New York, United States, June 01, 2022 (GLOBE NEWSWIRE) -- Point-of-care (POC) diagnostic device is regarded as an instrument that is used mainly to acquire any particular clinical information of the patients in clinical as well as resource-limited settings. Rapid diagnostic tests (RDTs) are known as a type of point-of-care (POC) diagnostic, which means that these assays are intended to provide diagnostic results much more conveniently to the patient as compared to the other tests. The key factors that are accelerating the overall growth rate of the Global Point of Care & Rapid Diagnostics Market are the rise in cases of various infectious diseases worldwide, the increase in the conduction of POC tests, and the rise in usage of saliva as a liquid biopsy. In terms of Products, the ‘Glucose Monitoring Products’ segment held the largest proportion of the share of around 42.96% in 2020. On a regional basis, North America held the largest share, with nearly 40.72% of the entire market. However, the Asia-Pacific (APAC) region was regarded as the fastest growing market with a robust CAGR throughout the prevised period of 2020 to 2030.
To get a first-hand overview of the report, Request a Sample at
https://www.strategicmarketresearch.com/request-sample/point-of-care-diagnostics-market
The report promulgated by Strategic Market Research on the Point of Care & Rapid Diagnostics Market is ramified on the basis of:
Product
· Glucose Monitoring Products
· Coagulation Monitoring Products
· Drugs-of-abuse Testing Products
· Fecal Occult Testing Products
· Infectious Disease Testing Products
· Pregnancy & Fertility Testing Products
· Cholesterol Testing Products
· Cardiometabolic Monitoring Products
· Cancer Marker Testing Products
· Urinalysis Testing Products
· Hematology Testing Products
· Other POC Products
Mode of Purchase
· Prescription-based Testing Products
· OTC Testing Products
Platform
· Lateral Flow Assays
· Microfluidics
· Immunoassays
· Dipsticks
· Molecular Diagnostics
End-User
· Home Care
· Hospitals and Critical Care Centers
· Outpatient & Ambulatory Care Facilities
· Others
Regions:
North America
- USA
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- Finland
- Switzerland
- France
- Russian Federation
- U.K
- Finland
- Turkey
- Netherlands
- Belgium
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Indonesia
- South Korea
- Thailand
- Singapore
- Malaysia
- Philippines
- New Zealand
- Australia
- Rest of APAC
LAMEA
- Brazil
- Uruguay
- Saudi Arabia
- Argentina
- Rest of LAMEA
Make a Direct Purchase of the latest Point of Care and Rapid Diagnostics Market Latest Report. Click the below link to initiate the purchase:
https://www.strategicmarketresearch.com/buy-now/point-of-care-diagnostics-market
| Report Coverage | Details | |
| Forecast Period | 2020-2028 | |
| Forecast Period 2021 to 2028 CAGR | 11.78% | |
| 2028 Value Projection | USD 70.231 | |
| Base Year | 2020 | |
| Market Size in 2020 | 29.638 billion | |
| Historical Data for | 2015 - 2019 | |
| No. of Pages | 135 | |
| Companies | Glucose Monitoring Products, Infectious Disease Testing Products, Coagulation Monitoring Products, Fecal Occult Testing Products, Cardiometabolic Monitoring Products, Pregnancy& Fertility Testing Products, Cholesterol Testing Products, Cancer Marker Testing Products, Urinalysis Testing Products, Hematology Testing Products, Drugs-of-abuse Testing Products, Other POC Products | |
| Leading Segment Based on Product | Glucose Monitoring Products | |
| Leading Region | North America | |
| Segments covered | Based on Product, Based on Mode of Purchase, Based on Platform, Based on End-User, and Regional Analysis: | |
| Growth Drivers | Rising Occurrence of Infectious Diseases, Rise in Older Population, Minimally Invasive Surgeries, Percutaneous Coronary Intervention Procedures | |
Pivotal factors driving the Market Growth:
- The continuous rise in the prevalence of infectious diseases across the globe is one of the major reasons that is fuelling the overall market growth. The WHO (World Health Care Organization) has announced that approximately 17 million people die each year from infectious diseases.
- Apart from the rise in infectious diseases, the Lab-on-a-chip technology is also a key factor driving the market growth as it enables the various bioassays such as PCR & ELISA tests to be conducted at the different POC centres. As per BioRad, the typical range of detection for an ELISA test is (0.1 to 1) fmole or 0.01 ng to 0.1 ng, with its sensitivity depending upon the different characteristics of the antibody-antigen interaction.
- Furthermore, the rise of several POC testing processes like urine tests, pregnancy tests, and Neuropsychological tests are augmenting the market growth significantly.
In terms of Products, the ‘Glucose Monitoring Products’ segment dominated the market.
In terms of Products, the market is ramified into Glucose Monitoring Products, Coagulation Monitoring Products, Drugs-of-abuse Testing Products, Fecal Occult Testing Products, Infectious Disease Testing Products, Pregnancy & Fertility Testing Products, Cholesterol Testing Products, Cardiometabolic Monitoring Products, Cancer Marker Testing Products, Urinalysis Testing Products, Hematology Testing Products, and Other POC Products. The ‘Glucose Monitoring Products’ segment held the highest share of nearly 42.96% in 2020. The continuous increase in demand for home glucose testing, rise in the number of patients from infectious diseases& the adoption of highly advanced technologies among the researchers worldwide are augmenting the growth of this segment. As per VeryWell Health, Home blood glucose meters are only considered as clinically accurate if the result is within a range of around 20% of what a lab test would indicate. A glucose meter result of 100 mg/dL can vary on the downside up to 80 mg/dL or on the upside to 120 mg/dL & still be considered accurate.
In terms of Mode of Purchase, the ‘OTC Testing Products’ segment held the largest market share.
Based on Mode of Purchase, the market is ramified into prescription-based testing products & OTC testing products. The ‘OTC Testing Products’ segment held the highest share in 2020 due to the rising demand for early detection of diseases & growing awareness of the usage of POC products worldwide. As per a research study, it was figured out that there are more than 300,000 marketed OTC drug products. Around 9 out of every 10 people in the United States use OTC medications on a daily basis.
In terms of Platform, the ‘Lateral Flow Assays’ segment held the largest market share.
For Platform, the market is bifurcated into Lateral Flow Assays, Immunoassays, Microfluidics, Molecular Diagnostics, and Dipsticks. The ‘Lateral Flow Assays’ held the highest revenue of around USD 8.27 billion in 2020 due to the increase in LFA-based POC devices & a rise in awareness of the various advantages associated with POC testings.
In terms of End-User, the ‘Hospitals & Critical Care Centres’ segment held the most significant share of the market in 2020.
For End-User, the market is segmented into Hospitals and Critical Care Centers, Home Care, Outpatient and Ambulatory Care Facilities, and Others. The ‘Hospitals and Critical Care Centres’ held the largest market share in 2020. The AHA (American Hospital Association), declared that there are a total of 6090 hospitals in USA out of which there are around 2946 Nongovernment Not-for-Profit Community Hospitals, approximately 962 Local & State Government Community Hospitals, nearly 1233 Investor-Owned Community Hospitals, around 625 Non-Federal Psychiatric Hospitals, close to 208 Federal Government Hospitals, & around116 other types of hospitals.
North America held the maximum share during the forecasted period.
North America spearheaded the POC diagnostics market in 2020, with a decent CAGR of 9.83% because of the rise in awareness of self-testing, highly favourable government policies, etc. In 2020, the United States Point of Care (POC) Diagnostics Market size summed up to USD 5.83 billion.
The Point of Care Diagnostic Market in Europe is estimated to be the 2nd-largest market after North America. UK, France, & Deutschland are the 3 most dominant countries in the POC diagnostics market of the European Union.
On the other hand, Asia Pacific is the fastest-growing region of the POC diagnostics market. The POC Diagnostics Market in the Asia Pacific region is growing comprehensively with a steady CAGR & is expected to reach up to USD 7.98 billion by 2028. In China and India, the higher growth potential of the organizations in the development & distribution of point of care devices is augmenting the market growth of this region.
Before initiating a purchase, make a Pre-order enquiry and get a detailed overview of the content of the report.
https://www.strategicmarketresearch.com/pre-order-enquiry/point-of-care-diagnostics-market
Key players existing in the Point of Care and Rapid Diagnostics Market:
- Roche Diagnostics
- Abbott Laboratories
- Danaher Corporation
- Siemens Healthineers
- Becton Dickinson and Company
- Quidel Diagnostics
- EKF Diagnostics
- Chembio Diagnostics
- Trinity Biotech
- Fluxergy
Kindly go through and get access to our comprehensive coverage of myriad number of Healthcare reports published in the last three months:
https://www.strategicmarketresearch.com/reports/healthcare
Recent Developments:
- On April 4th 2022, the CDC (Centres for Disease Control & Prevention) introduced some of the major guidelines on SARS-CoV-2 Rapid Testing in Point-of-Care (POC) settings. This guidance provides accurate information on the various regulatory requirements for the conduction of SARS-CoV-2 rapid testing at the point-of-care settings like the collection of specimens, performing rapid tests safely & correctly, and also convey the information accurately on reporting test results.
- On Oct 15th, 2021, the United States FDA successfully approved Roche’s TECENTRIQ. It was introduced as adjuvant therapy for people who were suffering from early stages of lung cancer. TECENTRIQ is by far the only existing cancer immunotherapy that is available for the adjuvant treatments of NSCLC (Non-Small Cell Lung Cancer Treatment)
- On Mar 27th, 2020, Abbott successfully introduced its Molecular Point-Of-Care test for the accurate detection of the COVID-19 virus that works within five minutes. It has been decided by the upper management that the test will continue to run on Abbot’s ID NOW platform, thus providing much quicker results in the healthcare facilities such as physician’s offices, urgent care clinics, & hospital emergency departments.
Related Reports:
Blood Glucose Monitoring Devices Market
SMR’s ‘Global Blood Glucose Monitoring Devices Market Report with Insights & Forecast 2030’ deciphers a concrete idea regarding the valuable market insights like the driving factors, restraining factors, opportunities, etc. The Global Blood Glucose Monitoring Devices Market valued up to USD 13.42 billion in 2020, & the market is predicted to expedite at a CAGR of 7.92% from 2021 to 2028. Key factors that are driving the market growth continuously are the rapid advancement of various technologies & early diagnosis of hypo- and hyperglycemia. The key organizations that are associated with the market are Roche (Switzerland), Abbott (US), LifeScan (US), Medtronic (Ireland), Dexcom (US), Ypsomed (Switzerland), B. Braun (Germany), Ascensia (Switzerland), etc.
SMR’s ‘Digital Therapeutics Market Report Insights & Forecast 2030’ highlights a pellucid concept about the crucial market insights like drivers, restraints, future opportunities, etc. In 2020, the Global Digital Therapeutics Market share summed up to USD 2.3 billion. It is forecasted to reach a benchmark of USD 35.78 billion by 2030, with a burgeoning CAGR of 31.4 %. The major driving factors of the market growth are the rise in cases of chronic diseases, increase in the focus on preventive health care, and larger adoption of mobile phones. The key organizations associated with it are Medtronic Plc.,Akili Interactive Labs, Inc. ,Fitbit, Happify, Inc., Click Therapeutics, Inc., Kaia Health, Livongo Health, Omada Health, etc.
SMR’s ‘Lateral Flow Assay Market Report Insights & Forecast 2030’ encompasses a wide range of understanding regarding the key market insights like restraining factors, opportunities, drivers, etc. The market size was anticipated to be around USD 8.4 billion in 2020, and the forecast suggests that by 2030, it would reach a benchmark of USD 12.85 billion, with a 4.34% CAGR. The essential factors that are fuelling the market growth are the rapidly rising geriatric population, higher prevalence of infectious diseases worldwide, rising demand for POC devices, Need for rapid diagnostic testing for COVID-19, and increasing use of Home-based lateral flow assay devices, etc. The key companies that are associated with this market are Abbott Laboratories, Quidel Corporation, F. Hoffman-La Roche AG, Danaher Corporation, Siemens AG, Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories, Thermo Fisher Scientific, etc.
SMR’s ‘Kidney Function Test Market Report Insights & Forecast 2030’ describes a comprehensive idea of the pivotal marketing insights like the key drivers, restraints, futuristic opportunities, etc. In 2020 the Global Kidney function test market accounted for USD 777.06 million. It is predicted to reach a landmark of USD 1160.93 billion by 2028, with a CAGR of 6.9%. The rising occurrences of various kidney diseases, increase in privileges for conducting kidney tests at home, and the increase in funding by the worldwide government for R&D activities, are proliferating the market growth. The organizations associated with this market are Unit Medical, Sysmex Corporation, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd., Randox Laboratories, Opti Medical, Nova Biomedical, etc.
SMR’s ‘Metabolomics Market Report Insights & Forecast 2030’ accurately outlines a clear conception regarding the crucial insights of the market, like drivers, opportunities, restraints, etc. In 2020, the Global Metabolomics Market share summed up to USD 1.9 billion and is forecasted to reach around USD 6.68 billion by 2030, representing a CAGR of 13.4 %. The pivotal factors that are enhancing the market growth are the massive growth of the geriatric population and increase in the government & private investments in R&D. Apart from that, the key players associated with this market are Waters Corporation, Merck KGaA, GE Healthcare, Hitachi High-Technologies Corporation, LECO Corporation (US), Metabolon, Inc., Bio-Rad Laboratories, Human Metabolome Technologies Inc., etc.
About Us:
Strategic Market Research facilitates the organizations globally in taking pivotal business decisions by furnishing the Syndicated and Customized Research Reports, which are highly precise in terms of market numbers. We believe that every firm, whether it is a startup which is in the Introduction stage of the Product Life cycle or an established one which is at the growth stage, requires market research services in order to streamline its key business blueprint. It may be related to Product Launch, Go to Market strategies, Competitive Analysis or new geographical penetration and expansion.
Contact Us:
Strategic Market Research LLP.
Sunil Kumar
US: +1-8317045538
UK: +441256636046
India: +91-8260836500
Email: info@strategicmarketresearch.com
Web: https://www.strategicmarketresearch.com
Blog: https://www.strategicmarketresearch.com/blog
Press Release: https://www.strategicmarketresearch.com/press-releases
Connect Us:
LinkedIn: https://www.linkedin.com/company/strategic-market-research/
Twitter: https://twitter.com/smrstrategic
Facebook: https://www.facebook.com/StrategicMarketResearch
Instagram: https://www.instagram.com/strategicmarketresearchsmr/
